Austar Lifesciences: No Share Capital Changes Recorded for September 2026; Public Float Remains Above 25% Threshold

Bulletin Express10-02

Austar Lifesciences Limited reported that its authorised and issued share capital remained unchanged during September 2026.

Total authorised share capital stood at HKD 100.00 million, representing 10.00 billion ordinary shares with a par value of HKD 0.01 each. Issued share capital was unchanged at 512.58 million ordinary shares, and the company held no treasury shares at month-end.

Austar Lifesciences confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25% of issued shares. No share options, warrants, convertibles or other equity instruments were granted, exercised or cancelled during the month, and there were no share buy-backs or redemptions.

The monthly return was submitted on 2 October 2026 by Company Secretary Mak Yuk Kiu.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment